Fractyl Health (GUTS) Reports Positive Randomized Data from REMAIN-1 Midpoint Cohort Demonstrating Durable Weight Maintenance One Year After GLP-1 Discontinuation

Up to 84% of GLP-1 induced weight loss retained with Revita® versus 46% with sham at one year in patients receiving complete duodenal ablations

Next anticipated Revita® milestones are topline six-month randomized data from the REMAIN-1 Pivotal Cohort in early Q4 2026 and a potential FDA De Novo marketing application submission in late Q4 2026

Company to host investor webcast today at 8:00 a.m. ET.

Quite excited to see what they have to say.

Link to 8-K: [SEC Filing | Fractyl Health, Inc.](https://ir.fractyl.com/node/8881/html)